

Lecture Objectives


- At the conclusion the audience should have a better understanding of


 - Understand disease specific serologic testsUnderstand laboratories which are prognostic in chronic liver disease

Clinical Scenario

- You follow a 65 year old male at VA clinic
- His ALT is 58 IU/ml (within normal limits)
- On a rotation through cardiology, you see him
- He is to be started on a statin, his ALT at LUMC is 55 IU/ml (H)
- He asks you what this means?

10.5 The left depicts 177 overweight patients undergoing routine surgery The right depicts 629 patients undergoing evaluation for HCV





Significant disease can occur at "normal"

- G3/458 patients had a liver biopsy with an ALT < 40 U/L (long standing steatosis)
 Mean ALT was 28 ± 7 U/L
 Fibrosis ≥ 2 (moderate) was seen in 22% with "normal" ALT and 34% with increased ALT (p=ns)
- met more stringent criteria for normal Fracanzani Hepatology 2008 ;48:792-798

Conclusions

- Most laboratories use > 2 SD to define
 - The differences in clinical laboratories abnormal is based on the health of the reference population
- There is difficulty defining "normal" so your clinical suspicion for disease should must supersede labs
- A "normal" ALT does not exclude liver disease or histologic damage

Who to test?

- No recommendation to routinely test healthy,
- Screened disease

 - Limited data (Lack of population based data)
 - Effective intervention should exist
 Limited interventions for some diseases (NAFLD)


- NHANES III data Used ALT > 40 for men and > 31 for women as abnormal

- Prevalence of abnormal aminotransferases was 7.9% Men 9.3%, women 6.6% Hispanic 14.9%, African American 8.1% and non-Hispanic white 7.1% Only 31% of cases had an etiology for abnormal aminotransferases (viral hepatitis, alcohol, iron overload)
- If more stringent criteria for abnormal ALT used 26% had an elevated ALT, of which 21.2% had no explanation

LFTS: Worrisome? AP 99 • AST 560 ALT 901 • Alb 2.1 • PT 66 Listing for fulminant hepatic failure requires onset of encephalopathy within 8 weeks of onset of liver disease symptoms and one of the following: 1) ventilator dependence, 2) requiring renal replacement therapy or 3) INR > 2.0

Interpretation of Liver Tests

- True "liver function tests"
- Hepatocellular damage
- Cholestasis
- Are the abnormalities noted acute or chronic?



True Liver Function Tests

- Albumin

 Low albumin: edema, anasarca
 Nephrotic syndrome, malnutrition, protein losing enteropathy

 Prothrombin time

- High PT/INR: increased risk of bleedingVitamin K deficiency, consumptive coagulopathy
- Bilirubin
 - Jaundice (total bilirubin > 2-3 mg/dL)
- Cholesterol

Prolonged PT

thromboplastins for patients on warfarin

- There is significant variation in INR from lab to lab in cirrhotic patients
- Common clinical dilemma- vitamin K deficiency, consumptive coagulopathy or

Factor	Cirrhosis	Vit K def	Consumption
Abnormal V	Yes	No	Yes
Abnormal VII	Yes	Yes	Yes
Abnormal VIII	No	No	Yes

Markers of Hepatocyte Damage

- ALT (alanine aminotransferase--SGPT)
 - Cytosol of hepatocytesMore hepatocyte specific
- AST (aspartate aminotransferase--SGOT)

 Cytosol and mitochondria
 Muscle, intestine, brain, kidney, pancreas, red blood cells
 - Mitochondrial induction/damage by alcohol explains higher AST levels in persons consuming excessive ETOH, vitamin deficiency leads to lower ALT

■ Lactate dehydrogenase (LDH) Can be markedly elevated in shock liver

Causes of Markedly Elevated Aminotransferase Levels (> 1,000 U/L)

- Drug/toxin induced injury

 - NOT alcohol alone
- Acute viral hepatitis
- Shock liver
- Autoimmune hepatitis
- Common bile duct stone

ALT/AST ratios

- Accompanying hemolytic anemia Advanced fibrosis
- - AST/ALT ratio >1 had a sensitivity of 41%, a specificity of 78% to identify advanced fibrosis Unpublished data

Markers of Cholestasis

- Localized in microvilli of bile canaliculus
 Hepatic synthesis îî in cholestasis
 Fractionation can help

- Bone, intestine, placenta
- Gamma glutamyl transferase (GGT)
 Induced by alcohol, medications
- 5′-Nucleotidase
- Bilirubin

Cholestasis

Gilbert's syndrome Crigler-Najjer syndrome Hemolysis Hematoma resorption Bile duct obstruction Severe hepatitis Cirrhosis Medication/Toxin PBC PSC Sepsis TPN Benign recurrent cholestasis Vanishing bile duct syndrome Dubin-Johnson syndrome Rotor syndrome

Hepatobiliary Bile duct obstruction PBC PSC Medications Hepatic metastasis Severe hepatitis Cirrhosis Vanishing bile duct syndrome Benign recurrent cholestasis Infiltrating diseases Sarcoid TB Fungal Amyloidosis Heme malignancy

Bilirubin Metabolism

- Bilirubin is a normal heme degredation product
 Predominant excretion is in bile
 Unconjugated (indirect) is taken up by hepatocytes
 Conjugated (direct) by the endoplasmic reticulum using enzyme bilirubin UDP-glucuronyltransferase
 Water soluble bilirubin glucuronides secreted across canicular membrane into bile

 - Clinical correlate: Gilbert's syndrome
 Diminshed expression of bilirubin UDP-glucuronyltransferase
 Up to 5% of population
 Benign, unconjugated hyperbilirubinemia
 Can be worsened by stress, fasting

First Approach

- - Many will normalize without intervention, ONLY consider if no risk factors are present
 - Discontinue alcohol, potential hepatotoxins
 - Would not wait however if there are signs of
- Continued Elevation
 - Work up is based on pattern of abnormalities

 - Acute versus Chronic


Clinical scenario


- A 55 year old man is admitted overnight, he is new to LUMC and presents with melena
- On US he has a nodular appearing liver with possible fatty infiltration
- Relevant labs ALT 55, AST 77, TB 0.9, AP 88, PLT 55, HGB 8.9
- He undergoes endoscopy finding recently bleeding varices which were banded

Continued

- Which of the following labs sent over night are
- Acute hepatitis panel (hep A IgM, HBS AG, Anti-HBV core AB total, Anti-HCV)
- ANA, ASMA, AMA
- Alpha-1 antitrypsin
- Ferritin, iron, TIBC
- Serum alcohol

The "shotgun"	approach
■ HAV IgM ←	Chronic hepatitis?
 HBV s Ag, core IgM 	
 Anti-HCV 	
• AMA	Is there cholestasis?
 ANA, ASMA 	
• Ceruloplasmin *	Patient age?
 Alpha-1 antitrypsin 	
 Iron, TIBC, ferritin 	
 Tox screen 	
 RUQ US 	
 Consider Biopsy 	





Patient Characteristics Risk factors (HCV): IVDA (viral, EtOH) Blood transfusions

• Medications:

AntiepilepticsHAARTINH

- Sex:

 Female (AIH, PBC)
 Male (PSC)

 Age:

 Neconatal (A1AT)
 < 40 (Wilson's, AIH)
 > 40 (viral, HFE)
- - - Comorbidities:
 - DM/obesity: NASHCHF: HFE

Tattoos

- Family HxA1AT deficiency
- Country of Birth

HBV

Historical Clues

	Disease Correlation
Remote history of jaundice	Viral hepatitis
Medical history of autoimmune diseases	AIH
Hypothyroidism	AIH, PBC
History of liver disease as a newborn	Alpha-1 antitrypsin deficiency
Family history of liver disease	HBV, hemochromatosis
History of alcohol abuse, DUI	Alcohol
History of IVDA, blood transfusion prior to 1990	HCV
Diabetes	Hemochromatosis, NAFLD
Components of Metabolic Syndrome	NAFLD
Medications, CAM therapy	Drug induced liver injury
Pruritis	PBC
Ulcerative Colitis	PSC
Arthritis	Hemochromatosis, HCV


Physic	cal Clues
Physical Exam Findings	Disease Correlates
Spider angiomas	Cirrhosis
Palmar erythema	Cirrhosis
Splenomegaly	Portal hypertension
Jaundice	Cirrhosis, Biliary obstruction, hemolysis, Gilbert's
Hyperpigmentation	Hemochromatosis
Kayser-Fleisher rings	Wilsons disease
Emphysema/Lung disease	Alpha-1 antitrypsin deficiency
Ascites	Portal hypertenson, cirrhosis
Asterixis	Portal hypertension
Xanthalasma	PBC
And	

Liver Disease

- evaluation of liver disease with a basic understanding of each individual disease
- The next section will focus on serology of chronic liver diseases

Hepatocellular causes

Disorder	Acute	Chronic
Hepatitis A	+	
Hepatitis B	+	+
Hepatitis C	+	+
Hepatitis E	+	(rare)
Autoimmune hepatitis	+	+
Wilson Disease	+	+
Hemochromatosis		+
Alpha-1 AT deficiency	(neonatal)	+
NAFLD		+
Alcohol	+	+
Medication/Toxin	+	+



1	Diag	nosis	of HB\	/	
	HBsAg	HBc	HBe	HBsAb	HBV DNA
Acute	HBsAg	HBcIgM			+
Chronic (immune tolerant or active)	HBsAg	HBcIgG	HBeAg+ or eAg-		>10 ⁴ - 10 ⁵
Inactive Carrier	HBsAg	HBcIgG	eAb+		< 10 ⁴
Immune		HBcIgG		HBsAb	
Vaccinated		The A		HBsAb	

HCV lab tests

HCV test	Comment
Anti-HCV	Seropositive in past and current infection
HCV RIBA	Seldom used Can distinguish false positive AB from past infection
HCV RNA	Viremia indicates current infection Viral load does not correlate with severity of liver disease
HCV genotype	Measure if considering interferon based therapy Genotype 1 predominates in US

Hemochromatosis LABS: iron/TIBC, ferritin, genotype Clinical suspicion Fatigue, arthralgia, diabetes mellitus, hyperpigmentation, impotence Transferrin saturation and ferritin TS > 45% Sensitivity >97% Specificity 45% Ferritin > 1000 mg/ml marker of significant disease Genotype C282Y (prevalence 5/1000 if Northern European descent) Accounts for 80-85% of typical hemochromatosis Only 10% of C282Y homozygotes will have end organ damage Other mutations: ie H63D, S65C controversial

Autoimmune Hepatitis

- - Interfactor
 Less hyperglobulinemia
 Tends to be more severe at onset and more likely to progress to cirrhosis

		on's
BS: ceruiopiasmii Test	n, 24 urine cop WD	per, serum copper, genetic testing Comments
Ceruloplasmir	n <20 mg/dl	95% homozygotes 20% heterozygotes
Slit-lamp	KF rings	Absent early F(+) cholestatic disease
24 hour urine	>100 ug	F(-) early F(+) cholestatic disease
Hepatic copper	>250 ug/g	F(+) cholestatic disease F (-) sampling error

Alpha-1 Antitrypsin Deficiency

- LABS: alpha1-antitrypsin level, phenotype
- Serine protease inhibitor for which liver disease results from failure to export
- History 10% develop neonatal hepatitis or obstructive jaundice Serum levels

- Phenotyping

 PiZZ
 Liver histology
 A1AT globules in ER of periportal hepatocytes
 PAS positive, diastase-resistant

- NASH

 3% of general population
 20% of obese individuals

 Disease associations

 Metabolic syndrome
 Visceral obesity, insulin resistance, dyslipidemia (HDL, TG), elevated blood pressure

 Asymptomatic transaminase elevation

 ALT > AST
 GGT may be increased
 Alk phos usually < 2x ULN
 Elevated ferritin 60% (marker for IR)

NAFLD

Alcoholic Hepatitis

- Diagnosis-History

 Ask about DUI
 AST>>ALT (both typically < 300 U/L)
 Elevated bilirubin and prolonged PT
 Alkaline phosphatase often normal
 Calculate discriminant function
 Compute the second se

 - Serum bilirubin + 4.6*(patient PT- control PT)
- DF > 32 is important
 Designates poor prognosis, high mortality
 Marker for therapy consideration

 Prednisolone, pentoxifylline

Hepatotoxic Medications

- Commonly prescribed Medication Augmentin Anti-Epileptics Azole (antifungal) Isoniazid Anesthetics Halothane Nicrotinic acid Nitrofurantion Propylthiouricil Oral hypoglycemics Clyburide Typoglycemics
- inhibitors Protease inhibitors

- OTC, CAM, illicit Acetaminophen

 - Ephedra
 - Kava
 - Chaparral
 - Black Cohosh
 - Ecstasy
 - Hydrofluorocarbons

LFT's and Stating

Chronic aminotransferase elevation and histological injury has never been convincingly proven

- Significant hepatotoxicity attributable to statins is
- Use of lower doses and highly lipophilic (cerivastatin, lovastatin, simvastatin) may reduce hepatotoxicity

Highly Lipophilic 1.58 0.81, 3.05
Mildly Lipophilic 3.54 1.72, 5.58

Argo et al Hepatology 2008;48:662

	Table 1 Ir	cidence of Amir	Disea otransferase Elevation		Cardiovascular Diseau	se.
Study	Year	Agent	Multiple Assessments of AST or ALT	Statin (%)	Placebo (%)	Total (%)
EXCEL	1991	Lovastatin	Yes	45/6,582 (0.6)	2/1,663 (0.1)	47/8,245 (0.6)
4S	1994	Simvastatin	No	49/2,221 (2.2)	33/2,223 (1.5)	82/4,444 (1.8)
ACAPS	1994	Lovastatin	No	6/460 (1.3)	6/459 (1.3)	12/919 (1.3)
CRISP	1994	Lovastatin	Yes	0/289 (0)	0/142 (0)	0/431 (0)
Oxford	1994	Simvastatin	No	0/414 (0)	2/207 (1.0)	2/621 (0.3)
WOSCOPS	1995	Pravastatin	No	16/3,302 (0.5)	12/3,293 (0.4)	28/6,595 (0.4)
KAPS	1995	Pravastatin	No	4/224 (1.8)	3/223 (1.3)	7/447 (1.6)
CARE	1996	Pravastatin	No	66/2,081 (3.2)	73/2,078 (3.5)	139/4,159 (3.3)
LCAS	1997	Fluvastatin	Yes	2/214 (0.9)	0/215 (0)	2/419 (0.5)
AFCAPS-TEXCAPS	1998	Lovastatin	Yes	18/3,242 (0.5)	11/3,248 (0.3)	29/6,490 (0.4)
LIPID	1998	Pravastatin	No	95/4,512 (2.1)	85/4,502 (1.9)	180/9,014 (2.0)
LIPS	2002	Fluvastatin	Yes	10/844 (1.2)	3/833 (0.4)	15/1,677 (0.9)
PROSPER	2002	Pravastatin	No	1/2,891 (0)	1/2,913 (0)	2/5,804 (0)
Total				312/27,276 (1.1)	231/21,999 (1.1)	543/49,275 (1.
Odds ratio				1.26 (NS)	1.00	

Cholestatic Liver Disease

		Chronic	
PBC		+	
PSC		+	
Obstructive Jaundice	+(pain)	+	
Medications/Toxins	+	+	

Medications/Toxins	+	+	

PBC

- LABS: AMA, immunosglobulins
- LABS: AMA, immunosglobulins
 Serologic

 Anti-mitochondrial antibody (AMA)
 95% positive in PBC
 1% general population
 5% PBC patients AMA negative
 Targets mitochondrial specific complexes
 High levels of IgM
 Alkaline phosphatase elevation > aminotransferases
 Increased bilirubin associated with worsened disease severity
 High cholesterol (especially HDL)




Medicines that Cause Cholestasis

- Anabolic steroids Allopurinol Amoxicillin-clavulanic acid Atazanavir Diltiazem Erythromycin Estrogens Indinavir Nevirapine Methyltestosterone Quinidine Total parenteral nutrition Trimethoprim-sulfamethoxazole

Surveillance for HCC AASLD recommends US (and AFP*) every 6-12 months for surveillence

- □ Hepatitis B carriers
 Asian males ≥ 40
 Asian females ≥ 50
 Cirrhosis at any age
 Positive family history
 Africans ≥ 20
- Anitalise 200
 For those not listed above HCC risk varies; consider HBV viral load and grade of inflammation
- Non-hepatitis B Cirrhosis
- Hepatitis CAlcohol
- PBC
- Alpha-1 antitrypsinNASH

- Bruix Hepatology 2010 (AASLD position paper) *AFP was dropped from 2010 guidelines




Clinical scenario

- A 45 year old woman sees you in follow up.
- She has HCV and alcohol cirrhosis, but
- Her labs include CR 0.8, TB 0.9 and INR 1.1, AST 66, ALT 48
- She recently saw hepatology and was told she did not need transplant
- As her primary care doctor she asks if you agree

Severity of Liver Disease

- Child-Turcotte-Pugh System (CTP) Not formally validated as prognostic tool Useful means to rapidly assess prognosis Also useful for pre-operative risk assessment Semi-Subjective Model for End stage Liver Disease (MELD) Currently used for transplant listing Based on creatinine, INR, total bilirubin (Cr and INR more heavily weighted) Objective values comprise score Validated to predict survival 3 month survival for a MELD of 6 20% 0 7% Maincher Hepatolog 200



		P score	
	100		
		2 points	3 points
Grade encephalopathy	None	1-2	3-4
	Absent	Slight	Moderate or more
Bilirubin	1-2	2-3	>3
Bilirubin (for PBC patients)	1-4	4-10	>10
Albumin	>3.5	2.8-3.5	<2.8
INR	<1.7	1.7-2.3	>2.3

Important Disease Assocations

- □ Cirrhosis, DM, arthritis, AFIB
- IBD and elevated alkaline phosphatase
- Viral hepatitis associated with liver failure in
- Liver disease, with anemia and psychosis
- ALT greater than 5000 in someone with alcoholism
- Elevated alkaline phosphatase with itching and fatigue seen in a 50 year old woman

Case 1

- A 25 year old presents 3 days after a significant
- There is AMS and they are intubated early in the course- NAC is started

Lab	Day 1	Day 2	Day 3
TB	3.2	4.1	4.8
AST	12000	13000	9000
ALT	9000	10000	8500
INR	3.0	4.1	5.3

By Day 3 is the course better, worse or stable?

Case 2

- A person is referred for initial elevation in ALT (52)- synthetic function is normal and there are no prior available liver tests
- Ultrasound one year prior suggested a fatty
- Clinical history includes a blood transfusion in 1988 for a trauma, DM, BMI 29 and a family history of cancer in the liver but might have been metastatic
- Medications include metformin, losartan and atorvastatin

Conclusions

- When evaluating suspected liver disease
- Realize that aminotransferases are imperfect markers of disease state
- Following synthetic function is of vital importance
 Remember medications and complementary medicines
- Approach patients based on risk factors and pattern of liver injury (hepatocellular or cholestatic)
 Use models to assess severity of liver injury